JEIL PHARMACEUTICAL secures South Korea rights for Shionogis antibiotic Petrozajoo JEIL PHARMACEUTICAL prepares to enhance ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

A clinical trial by Shionogi is a milestone in the search to treat Jordan's Syndrome, a rare genetic disorder named after a California lobbyist's daughter.

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

Iwasaki attributed the decision to shifts in business strategies and emphasized that Shionogi will focus on new drug launches in China, including Phase 3-completed Cefiderocol and Naldemedine.

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial ...

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...